Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines

Authors: Reza Bayat Mokhtari, Sushil Kumar, Syed S Islam, Mehrdad Yazdanpanah, Khosrow Adeli, Ernest Cutz, Herman Yeger

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Bronchial carcinoids are pulmonary neuroendocrine cell-derived tumors comprising typical (TC) and atypical (AC) malignant phenotypes. The 5-year survival rate in metastatic carcinoid, despite multiple current therapies, is 14-25%. Hence, we are testing novel therapies that can affect the proliferation and survival of bronchial carcinoids.

Methods

In vitro studies were used for the dose–response (AlamarBlue) effects of acetazolamide (AZ) and sulforaphane (SFN) on clonogenicity, serotonin-induced growth effect and serotonin content (LC-MS) on H-727 (TC) and H-720 (AC) bronchial carcinoid cell lines and their derived NOD/SCID mice subcutaneous xenografts. Tumor ultra structure was studied by electron microscopy. Invasive fraction of the tumors was determined by matrigel invasion assay. Immunohistochemistry was conducted to study the effect of treatment(s) on proliferation (Ki67, phospho histone-H3) and neuroendocrine phenotype (chromogranin-A, tryptophan hydroxylase).

Results

Both compounds significantly reduced cell viability and colony formation in a dose-dependent manner (0–80 μM, 48 hours and 7 days) in H-727 and H-720 cell lines. Treatment of H-727 and H-720 subcutaneous xenografts in NOD/SCID mice with the combination of AZ + SFN for two weeks demonstrated highly significant growth inhibition and reduction of 5-HT content and reduced the invasive capacity of H-727 tumor cells. In terms of the tumor ultra structure, a marked reduction in secretory vesicles correlated with the decrease in 5-HT content.

Conclusions

The combination of AZ and SFN was more effective than either single agent. Since the effective doses are well within clinical range and bioavailability, our results suggest a potential new therapeutic strategy for the treatment of bronchial carcinoids.
Appendix
Available only for authorised users
Literature
1.
Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM: Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008, 113: 2655-2664. 10.1002/cncr.23883.CrossRefPubMed
2.
Pusceddu S, Catena L, Valente M, Buzzoni R, Formisano B, Del Vecchio M, Ducceschi M, Tavecchio L, Fabbri A, Bajetta E: Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis. J Thor Disease. 2010, 2: 16-20.
3.
4.
Zuetenhorst JM, Taal BG: Metastatic carcinoid tumors: a clinical review. Oncologist. 2005, 10: 123-131. 10.1634/theoncologist.10-2-123.CrossRefPubMed
5.
Walther DJ, Peter JU, Bader M: 7-Hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin-producing tumors. Cancer. 2002, 94: 3135-3140. 10.1002/cncr.10592.CrossRefPubMed
6.
Neri D, Supuran CT: Interfering with pH regulation in tumors as a therapeutic strategy. Nat Rev Drug Discov. 2011, 10: 767-777. 10.1038/nrd3554.CrossRefPubMed
7.
Robertson N, Potter C, Harris AL: Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004, 64: 6160-6165. 10.1158/0008-5472.CAN-03-2224.CrossRefPubMed
8.
Pastorekova S, Kopacek J, Pastorek J: Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem. 2007, 7: 865-878. 10.2174/156802607780636708.CrossRefPubMed
9.
Arvidsson Y, Bergstrom A, Arvidsson L, Kristansson E, Ahlman H, Nilsson O: Hypoxia stimulates CXCR4 signaling in ileal carcinoids. Endocr Relat Cancer. 2010, 17: 303-316. 10.1677/ERC-09-0085.CrossRefPubMed
10.
Supuran CT: Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008, 7: 168-181. 10.1038/nrd2467.CrossRefPubMed
11.
Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM: Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS One. 2010, 5: 1-9.CrossRef
12.
Cianchi F, Vinci CM, Supuran CT, Peruzzi B, De Giuli P, Fasolis G, Perigli G, Pastorekova S, Papucci L, Pini A, Masini E, Puccetti L: Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther. 2010, 334: 710-719. 10.1124/jpet.110.167270.CrossRefPubMed
13.
Ishizuka J, Beauchamp RD, Townsend CMJR, Greeley GHJR, Thompson JC: Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol. 1992, 150: 1-7. 10.1002/jcp.1041500102.CrossRefPubMed
14.
Drozdov I, Kidd M, Gustafsson BI, Svejda B, Joseph R, Pfragner R, Modlin IM: Auto-regulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer. 2009, 115: 4934-4945. 10.1002/cncr.24533.CrossRefPubMedPubMedCentral
15.
Fu XW, Nurse CA, Wong V, Cutz E: Hypoxia-induced secretion of serotonin from intact pulmonary neuroepithelial bodies in neonatal rabbit. J Physiol. 2002, 539: 503-510. 10.1113/jphysiol.2001.013071.CrossRefPubMedPubMedCentral
16.
Potter C, Harris AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 2004, 3: 164-167.CrossRefPubMed
17.
Alvarez LJ, Turner HC, Zamudio AC, Candia OA: Serotonin-elicited inhibition of Cl- secretion in the rabbit conjunctival epithelium. Am J Physiol Cell Physiol. 2001, 280: 581-592.
18.
Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, Yu Y, Clouthier SG, Schwartz SJ, Wicha MS, Sun D: Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res. 2010, 16: 2580-2590. 10.1158/1078-0432.CCR-09-2937.CrossRefPubMedPubMedCentral
19.
Chaudhuri D, Orsulic S, Ashok BT: Antiproliferative activity of sulforaphane in akt-overexpressing ovarian cancer cells. Mol Cancer Ther. 2007, 6: 334-345. 10.1158/1535-7163.MCT-06-0404.CrossRefPubMedPubMedCentral
20.
Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T: Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. Cancer Res. 2001, 61: 6656-6659.PubMed
21.
Pitt SC, Chen H, Kunnimalaiyaan M: Phosphatidylinositol 3-kinase-akt signaling in pulmonary carcinoid cells. J Am Coll Surg. 2009, 209: 82-88. 10.1016/j.jamcollsurg.2009.03.006.CrossRefPubMedPubMedCentral
22.
Parnaud G, Li P, Cassar G, Rouimi P, Tulliez J, Combaret L, Gamet-Payrastre L: Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. Nutr Cancer. 2004, 48: 198-206. 10.1207/s15327914nc4802_10.CrossRefPubMed
23.
Roy SK, Srivastava RK, Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 2010, 5: 1-13. 10.1186/1750-2187-5-1.CrossRef
24.
Igarashi T, Jiang SX, Kameya T, Asamura H, Sato Y, Nagai K, Okayasu I: Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol. 2004, 17: 1259-1267. 10.1038/modpathol.3800176.CrossRefPubMed
25.
Dashwood RH, Ho E: Dietary agents as histone deacetylase inhibitors: sulforaphane and structurally related isothiocyanates. Nutrition Review. 2008, 66: 36-38.CrossRef
26.
Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H: Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol. 2009, 16: 481-486. 10.1245/s10434-008-0194-6.CrossRefPubMed
27.
Wang XF, Wu DM, Li BX, Lu YJ, Yang BF: Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. Phytother Res. 2009, 23: 303-307. 10.1002/ptr.2618.CrossRefPubMed
28.
Jiang H, Shang X, Wu H, Huang G, Wang Y, Al-Holou S, Gautam SC, Chopp M: Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem Res. 2009, 35: 152-161.CrossRefPubMedPubMedCentral
29.
Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov AV, Herr I: Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 2010, 70: 5004-5013. 10.1158/0008-5472.CAN-10-0066.CrossRefPubMed
30.
Lin LC, Yeh CT, Kuo CC, Lee CM, Yen GC, Wang LS, Wu CH, Yang WC, Wu AT: Sulforaphane potentiates the efficacy of Imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function. J Agric Food Chem. 2012, 60: 7031-7039. 10.1021/jf301981n.CrossRefPubMed
31.
Mastrangelo L, Cassidy A, Mulholland F, Wang W, Bao Y: Serotonin receptors, novel targets of sulforaphane identified by proteomic analysis in Caco-2 Cells. Cancer Res. 2008, 68: 5487-5491. 10.1158/0008-5472.CAN-07-6171.CrossRefPubMed
32.
Yan Z, Caldwell GW, Zhao B, Reitz AB: A high-throughput monoamine oxidase inhibition assay using liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004, 18: 834-840. 10.1002/rcm.1415.CrossRefPubMed
33.
Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R: Histone H3 lysine 4 demethylation is a target of nonselective anti depressive medications. Chem Biol. 2006, 13: 563-567. 10.1016/j.chembiol.2006.05.004.CrossRefPubMed
34.
Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, Yeger H: Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem cell. 2008, 26: 1818-1830. 10.1634/stemcells.2007-0724.CrossRef
35.
Idikio HA: Spindle checkpoint protein hMad2 and histone H3 phosphoserine 10 mitosis marker in pediatric solid tumors. Anticancer Res. 2006, 26: 4687-4694.PubMed
36.
Erikkson B: New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?. Curr Opin Oncol. 2010, 22: 381-386. 10.1097/CCO.0b013e32833adee2.CrossRef
37.
Al-Batran SE, Ducreux M, Ohtsu A: mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer. 2012, 130: 491-496. 10.1002/ijc.26396.CrossRefPubMed
38.
Dong M, Yao JC: mTOR inhibition, a potential novel approach for bronchial carcinoids. Endoc-Relat Cancer. 2011, 18: 115-118.CrossRef
39.
Cutz E, Yeger H, Pan J, Ito T: Pulmonary neuroendocrine cell system in health and disease. Curr Resp Med Rev. 2008, 27: 174-186.CrossRef
40.
Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM: Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors analysis of the phase 3, randomized, placebo-controlled radiant-2 study. Chest. 2013, 143 (4): 955-962. 10.1378/chest.12-1108.CrossRefPubMed
41.
Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, Pastorek J, Sly WS: Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA. 2000, 97: 2220-2224. 10.1073/pnas.040554897.CrossRefPubMedPubMedCentral
42.
Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Buchler MW, Salinkov AV, Herr I: Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011, 19: 188-195. 10.1038/mt.2010.216.CrossRefPubMed
43.
Li X, Xiang Y, Ma B, Qi X: Effects of acetazolamide combined with or without NaHCO3 on suppressing neoplasm growth, metastasis and aquaporin-1(AQP1) protein expression. Int J Mol Sci. 2007, 1: 229-240.CrossRef
44.
Righi L, Volante M, Rapa I, Tavaglione V, Inzani F, Pelosi G, Papotti M: Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer. 2010, 17: 977-987. 10.1677/ERC-10-0157.CrossRefPubMed
45.
Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K: Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Neuroendocrinology. 2012, 96: 228-237. 10.1159/000337257.CrossRefPubMed
46.
Jakubíková J, Sedlák J, Mithen R, Bao Y: Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol. 2005, 69: 1543-1552. 10.1016/j.bcp.2005.03.015.CrossRefPubMed
47.
Suppipat K, Park CS, Shen Y, Zhu X, Lacorazza HD: Sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells. PLoS One. 2012, 7: e51251-10.1371/journal.pone.0051251.CrossRefPubMedPubMedCentral
48.
Shafee N, Kaluz S, Ru N, Stanbridge EJ: PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Letter. 2009, 282: 109-115. 10.1016/j.canlet.2009.03.004.CrossRef
49.
Kaluz S, Kaluzová M, Stanbridge EJ: The role of extracellular signal-regulated protein kinase in transcriptional regulation of the hypoxia marker carbonic anhydrase IX. J Cell Biochem. 2006, 97: 207-216. 10.1002/jcb.20633.CrossRefPubMed
50.
Matsumoto S, Tanimoto T, Yoshida S, Ikeda M, Takeda M, Saiki C, Shimazu Y, Aoba T, Nasu M, Suzuki K: Effects of acetazolamide and 4-Aminopyridine on CO2-induced slowly adapting pulmonary stretch receptor inhibition in rats. Chem Senses. 2004, 29: 351-361. 10.1093/chemse/bjh038.CrossRefPubMed
51.
Shankar S, Ganapathy S, Srivastava RK: Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res. 2008, 14: 6855-6866. 10.1158/1078-0432.CCR-08-0903.CrossRefPubMed
52.
Sawaoka H, Kawano S, Tsuji S, Tsuji M, Gunawan ES, Takei Y, Nagano K, Hori M: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 1998, 274: 1061-1067.
53.
Jafarau G, Xie Y, Kullyev A, Liang B, Sze YJ: Regulation of extrasynaptic 5-HT by SERT function in 5-HT-absorbing neurons underscores adaptation behavior in C. elegans. J Neurosci. 2011, 31: 8948-8957. 10.1523/JNEUROSCI.1692-11.2011.CrossRefPubMedCentral
54.
Tsuta K, Liu DC, Kalhor N, Wistuba II, Moran CA: Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol. 2011, 136: 252-259. 10.1309/AJCPDXFOPXGEF0RP.CrossRefPubMed
55.
Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A: ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol. 2010, 5: 453-4599. 10.1097/JTO.0b013e3181ca063b.CrossRefPubMed
56.
Ravina E: The Evaluation of Drug Discovery from Traditional Medicines to Modern drugs. In Edited by Ravina E. Weinheim. 2011, Germany: WILEY-VCH Verlag & Co. KGaA. Boschstr Press
57.
Jee HG, Lee KE, Kim JB, Shin HK, Youn YK: Sulforaphane inhibits oral carcinoma cell migration and invasion in vitro. Phytother Res. 2011, 25: 1623-1628. 10.1002/ptr.3397.CrossRefPubMed
58.
Bryant CS, Kumar S, Chamala S, Shah J, Pal J, Haider M, Seward S, Qazi AM, Morris R, Semaan A, Shammas MA, Steffes C, Potti RB, Prasad M, Weaver DW, Batchu RB: Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Mol Cancer. 2010, 9: 10-16. 10.1186/1476-4598-9-10.CrossRef
59.
Camilleri M: LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil. 2011, 23: 193-200. 10.1111/j.1365-2982.2010.01643.x.CrossRefPubMed
60.
Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, Suestsugi M, Watanabe Y: Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res. 2010, 23: 263-270.CrossRef
61.
Brian Cornblatt S, Lingxiang Y, Albena T, Kostova D, Melanie E, Fahey JW, Singh NK, Min-Shue Chen A, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K: Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis. 2007, 28: 1485-1490. 10.1093/carcin/bgm049.CrossRefPubMed
Metadata
Title
Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines
Authors
Reza Bayat Mokhtari
Sushil Kumar
Syed S Islam
Mehrdad Yazdanpanah
Khosrow Adeli
Ernest Cutz
Herman Yeger
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-378

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells

Research article

Uptake of a web-based oncology protocol system: how do cancer clinicians use eviQ cancer treatments online?

Research article

Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982–2008: overall good news but with rising rates in the oropharynx

Research article

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

Research article

Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer

Study protocol

Values and options in cancer care (VOICE): study design and rationale for a patient-centered communication and decision-making intervention for physicians, patients with advanced cancer, and their caregivers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits